Antiphospholipid Syndrome

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1A |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  S |  |  |
|  |  |  |  |  |  |  |  |  |  | 2S |  |  |  |  |  |  |  P |  |  |
|  |  |  |  |  |  |  |  | 3P |  |  L |  |  |  | 4B |  |  |  I |  |  |
|  |  |  |  |  |  | 5T |  H |  R |  E |  E |  |  |  |  E |  |  |  R |  |  |
|  |  |  |  |  |  |  |  |  E |  |  |  | 6S |  |  T |  |  |  I |  |  |
|  |  |  |  |  |  |  |  |  G |  |  | 7H |  E |  P |  A |  R |  I |  N |  |  |
|  |  |  |  |  |  |  |  |  N |  |  |  |  C |  |  |  |  |  |  |  |
|  |  |  |  |  | 8C | 9A |  T |  A |  S | 10T |  R |  O |  P |  H |  I |  C |  |  |  |
|  |  |  |  |  |  |  U |  |  N |  |  H |  |  N |  |  |  |  |  |  |  |
|  |  | 11G |  E |  N |  E |  T |  I |  C |  |  R |  |  D |  | 12L |  U |  P |  U |  S |  |
|  |  |  |  |  |  |  O |  |  Y |  |  O |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  I |  |  |  |  M |  | 13E |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  M |  |  |  |  B |  |  L |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  M |  | 14T |  W |  O |  H |  I |  T |  |  |  |  |  |  |
|  |  |  |  |  |  |  U |  |  |  |  S |  |  S |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  N |  |  |  |  I |  |  A |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  E |  |  |  |  S |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

|  |  |
| --- | --- |
| **Across****5.** How many known APL antibodies are there? **7.** Pregnancy management for thrombosis is low molecular weight or unfractionated \_\_\_\_\_**8.** \_\_\_\_\_\_APLS is rare but life threatening complication of APLS **11.** Risk factor of primary APLS is \_\_\_\_\_\_marker HLA-DR7**12.** Liquid phase coagulation assay to detect APLS by\_\_\_\_\_\_anticoagulant **14.** A theory explained about thrombus formation in patients with APLS is  | **Down****1.** Treatment for inhibit platelet activation is **2.** Risk factor of Secondary APLS (40%) is **3.** Arterial and venous thrombus and /or \_\_\_\_\_\_\_\_loss are hallmark of APLS.**4.** Most common antibody seen in APLS are anti \_\_\_\_\_2 glycoprotein antibody **6.** Pregnancy loss in patients with APLS is common in \_\_\_\_\_\_\_\_or third trimester **9.** APLS is a multi systemic \_\_\_\_ disorder **10.** Antiphospholipid syndrome provokes \_\_\_\_\_\_in arteries and veins.**13.** Solid phase assay to detect APLS is |